PMC:6537946 / 18092-18787 JSONTXT

{"project":"0_colil","denotations":[{"id":"31106338-28779893-6300","span":{"begin":210,"end":211},"obj":"28779893"},{"id":"31106338-28779893-6301","span":{"begin":645,"end":646},"obj":"28779893"}],"text":"Despite recent improvements in mechanical circulatory-assist devices, it is hard to compete with the excellent median overall survival of 10.7 years for all patients who received transplants from 1982 to 2015 [8]. In particular, the mortality rate remains consistently low if the patient survives the critical first 12 months after the transplant: Long-term deaths are due mainly to infectious diseases in immunocompromised patients (e.g. multiorgan sepsis), immunosuppression-associated malignancies (such as post-transplant lymphoproliferative disease as a result of immunosuppression) and progressive cardiac allograft vasculopathy (Fig. 3) [8]. Future research should focus on these factors."}

{"project":"TEST0","denotations":[{"id":"31106338-210-215-6300","span":{"begin":210,"end":211},"obj":"[\"28779893\"]"},{"id":"31106338-221-226-6301","span":{"begin":645,"end":646},"obj":"[\"28779893\"]"}],"text":"Despite recent improvements in mechanical circulatory-assist devices, it is hard to compete with the excellent median overall survival of 10.7 years for all patients who received transplants from 1982 to 2015 [8]. In particular, the mortality rate remains consistently low if the patient survives the critical first 12 months after the transplant: Long-term deaths are due mainly to infectious diseases in immunocompromised patients (e.g. multiorgan sepsis), immunosuppression-associated malignancies (such as post-transplant lymphoproliferative disease as a result of immunosuppression) and progressive cardiac allograft vasculopathy (Fig. 3) [8]. Future research should focus on these factors."}

{"project":"2_test","denotations":[{"id":"31106338-28779893-28904613","span":{"begin":210,"end":211},"obj":"28779893"},{"id":"31106338-28779893-28904614","span":{"begin":645,"end":646},"obj":"28779893"}],"text":"Despite recent improvements in mechanical circulatory-assist devices, it is hard to compete with the excellent median overall survival of 10.7 years for all patients who received transplants from 1982 to 2015 [8]. In particular, the mortality rate remains consistently low if the patient survives the critical first 12 months after the transplant: Long-term deaths are due mainly to infectious diseases in immunocompromised patients (e.g. multiorgan sepsis), immunosuppression-associated malignancies (such as post-transplant lymphoproliferative disease as a result of immunosuppression) and progressive cardiac allograft vasculopathy (Fig. 3) [8]. Future research should focus on these factors."}

{"project":"MyTest","denotations":[{"id":"31106338-28779893-28904613","span":{"begin":210,"end":211},"obj":"28779893"},{"id":"31106338-28779893-28904614","span":{"begin":645,"end":646},"obj":"28779893"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Despite recent improvements in mechanical circulatory-assist devices, it is hard to compete with the excellent median overall survival of 10.7 years for all patients who received transplants from 1982 to 2015 [8]. In particular, the mortality rate remains consistently low if the patient survives the critical first 12 months after the transplant: Long-term deaths are due mainly to infectious diseases in immunocompromised patients (e.g. multiorgan sepsis), immunosuppression-associated malignancies (such as post-transplant lymphoproliferative disease as a result of immunosuppression) and progressive cardiac allograft vasculopathy (Fig. 3) [8]. Future research should focus on these factors."}